Results 41 to 50 of about 46,090 (276)

Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]

PLoS ONE, 2012
Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang, Wei-Peng Yong   +6 more
doaj   +1 more source

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway

Journal of Experimental & Clinical Cancer Research, 2023
Background Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether ...
Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao, Yabin Yu   +8 more
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis [PDF]

, 2012
Purpose The prognosis of patients with advanced and recurrent urothelial cancer (UC) is poor. Although cisplatin (CDDP)-containing chemotherapy is the most effective regimen in these patients, there is no other established chemotherapeutic regimen.
Tomohiro Matsuo, Ohba, Kojiro, Yuji Sagara, Nomata, Koichiro, Miyata, Yasuyoshi, Sakai, Hideki, Yasuyoshi Miyata, Kanetake, Hiroshi, Koichiro Nomata, Hiroshi Kanetake, Matsuo, Tomohiro, Sagara, Yuji, Kojiro Ohba, Hideki Sakai   +13 more
core   +1 more source

Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer

Frontiers in Oncology, 2022
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Gemcitabine is the most commonly used chemotherapy for the treatment of PDAC, but the development of drug resistance still remains challenging.
Xinyuan Li, Kai Li, Mengmeng Li, Xiaoyu Lin, Yu Mei, Xuemei Huang, Huanjie Yang   +6 more
doaj   +1 more source

Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.

PLoS ONE, 2021
Patients with urothelial carcinoma (UC) experience gemcitabine resistance is a critical issue. The role of hedgehog pathway in the problem was explored.
Yu-Hao Chang, Hoi-Lam Tam, Meng-Chien Lu, Huei-Sheng Huang   +3 more
doaj   +1 more source

Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer [PDF]

Cancer Research, 2020
Abstract Pancreatic cancer is characterized by an extensive and complex microenvironment, and is resistant to both chemotherapy and immune checkpoint blockade. The study by Principe and colleagues in this issue of Cancer Research proposes a combinatorial approach based on targeting the very mechanisms of resistance to gemcitabine, a ...
Eileen S. Carpenter, Nina G. Steele, Marina Pasca di Magliano   +2 more
openaire   +2 more sources

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review [PDF]

, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
Pavlakis, Nick, Ross Davey, Davey, Ross, Nick Pavlakis, Britta Stordal, Stordal, Britta   +5 more
core   +1 more source

Development of taxane resistance in a panel of human lung cancer cell lines [PDF]

, 2008
Using a selection process designed to reflect clinically relevant conditions, a panel of taxane-selected variants were developed to study further the mechanisms of resistance in lung cancer.
Keenan, Joanne, Breen, Laura, Murphy, Lisa, Clynes, Martin   +3 more
core   +1 more source

Gemcitabine and anthracyclines in platinum-resistant ovarian cancer

Annals of Oncology, 2006
Most of the patients with advanced ovarian cancer will recur after first-line platinum-based chemotherapy and need additional treatment. Gemcitabine (G) and Anthracyclines are active in this setting and their combination has shown synergistic antiproliferative activity in vitro, due to different mechanisms of action and non-overlapping toxicities.In ...
Galligioni, E., Arcuri, C., Sorio, R., Griso, C.   +3 more
openaire   +2 more sources